Pharmacogenetics and diseases of the colon

被引:9
作者
Hisamuddin, Irfan M.
Wehbi, Mohammad A.
Yang, Vincent W.
机构
[1] Emory Univ, Sch Med, Dept Med, Div Digest Dis, Atlanta, GA 30322 USA
[2] Emory Univ, Sch Med, Winship Canc Inst, Dept Hematol & Oncol, Atlanta, GA 30322 USA
关键词
colorectal cancer; dihydropyrimidine dehydrogenase; flavin monooxygenase 3; inflammatory bowel disease; pharmacogenetics; thiopurine S-methyltransferase;
D O I
10.1097/MOG.0b013e32801145c2
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Purpose of review The deciphering of the human genome sequence has enabled the identification of genetic polymorphisms that are responsible for inter-individual variation in the response to drug therapy. This field is referred to as pharmacogenetics. We review the impact of pharmacogenetics on therapy in diseases of the colon using three common variant enzyme systems as examples. Recent findings Many enzyme systems impact the treatment of diseases of the colon. Examples include thiopurine S-methyltransferase, dihydropyrimidine dehydrogenase and flavin monooxygenase 3. They affect the management of inflammatory bowel disease, colorectal cancer and the chemoprevention of colorectal adenoma by influencing the metabolism of their respective substrates, azathioprine/ 6-mercaptopurine, 5-fluorouracil and sulindac. Recent studies have implicated the significance of genetic polymorphisms in each of the three drug-metabolizing enzymes, which impacts on the therapeutic outcome of the stated diseases. These studies highlight the potential role of pharmacogenetics in the design of a therapeutic plan which would increase efficacy and limit toxicity. Summary Pharmacogenetics of drug-metabolizing systems continues to gain significance in the drug therapy of a variety of disease states including those of the gastrointestinal tract.
引用
收藏
页码:60 / 66
页数:7
相关论文
共 56 条
[1]   The anti-cancer drug 5-fluorouracil is metabolized by the isolated perfused rat liver and in rats into highly toxic fluoroacetate [J].
Arellano, M ;
Malet-Martino, M ;
Martino, R ;
Gires, P .
BRITISH JOURNAL OF CANCER, 1998, 77 (01) :79-86
[2]   Thiopurine methyltransferase genotype predicts therapy-limiting severe toxicity from azathioprine [J].
Black, AJ ;
McLeod, HL ;
Capell, HA ;
Powrie, RH ;
Matowe, LK ;
Pritchard, SC ;
Collie-Duguid, ESR ;
Reid, DM .
ANNALS OF INTERNAL MEDICINE, 1998, 129 (09) :716-718
[3]   The implications of polymorphisms in mammalian flavin-containing monoloxygenases in drug discovery and development [J].
Cashman, JR .
DRUG DISCOVERY TODAY, 2004, 9 (13) :574-581
[4]   Interindividual differences of human flavin-containing monooxygenase 3: Genetic polymorphisms and functional variation [J].
Cashman, JR ;
Zhang, J .
DRUG METABOLISM AND DISPOSITION, 2002, 30 (10) :1043-1052
[5]   The thiopurines: An update [J].
Coulthard, S ;
Hogarth, L .
INVESTIGATIONAL NEW DRUGS, 2005, 23 (06) :523-532
[6]  
Coulthard S. A., 2001, Pharmacogenomics Journal, V1, P254
[7]   Pharmacogenomics and metabolite measurement for 6-mercaptopurine therapy in inflammatory bowel disease [J].
Dubinsky, MC ;
Lamothe, S ;
Yang, HY ;
Targan, SR ;
Sinnett, D ;
Théorêt, Y ;
Seidman, EG .
GASTROENTEROLOGY, 2000, 118 (04) :705-713
[8]   A cost-effectiveness analysis of alternative disease management strategies in patients with Crohn's disease treated with azathioprine or 6-mercaptopurine [J].
Dubinsky, MC ;
Reyes, E ;
Ofman, J ;
Chiou, CF ;
Wade, S ;
Sandborn, WJ .
AMERICAN JOURNAL OF GASTROENTEROLOGY, 2005, 100 (10) :2239-2247
[9]   Thiopurine therapies - Problems, complexities, and progress with monitoring thioguanine nucleotides [J].
Duley, John A. ;
Florin, Timothy H. J. .
THERAPEUTIC DRUG MONITORING, 2005, 27 (05) :647-654
[10]   Azathioprine: current status and future considerations [J].
el-Azhary, RA .
INTERNATIONAL JOURNAL OF DERMATOLOGY, 2003, 42 (05) :335-341